Quick answer: Chronic pain affects 50.2 million American adults (CDC 2019) — more than cancer, diabetes, and heart disease combined. Yet the biomedical model’s focus on structural pathology and opioid management ignores the neurobiological reality: chronic pain is fundamentally a brain disease, driven by central sensitization, glial activation, neuroinflammation, and psychosocial amplification that persists and progresses independent of ongoing tissue damage. Functional pain medicine targets the neuroscience of central sensitization with multi-modal precision.
Central Sensitization: The Neuroscience of Chronic Pain
Central sensitization — the amplification of neural signals within the central nervous system leading to pain hypersensitivity — was formalized by Clifford Woolf 1983 (Nature) and has transformed pain science. In central sensitization, the spinal cord and brain become “wound up” — spinal dorsal horn neurons exhibit increased excitability, decreased activation thresholds, and expanded receptive fields. The result: pain occurs in response to stimuli that normally don’t hurt (allodynia), pain is disproportionate to the stimulus (hyperalgesia), and pain spreads beyond the original injury site (referred pain and spreading sensitization).
The CSI (Central Sensitization Inventory) — a validated 25-item questionnaire — identifies central sensitization syndrome in patients with widespread pain, fatigue, cognitive impairment, and sensory hypersensitivity. Conditions now understood to be primarily central sensitization disorders include: fibromyalgia, chronic fatigue syndrome/ME-CFS, irritable bowel syndrome, interstitial cystitis, temporomandibular disorder, tension headache, and complex regional pain syndrome. These conditions share a neurobiological mechanism — not vague psychosomatic presentations — and respond to interventions targeting central sensitization pathways.
Glial Activation and Neuroinflammation in Chronic Pain
Microglia — the resident immune cells of the CNS — play a pivotal role in chronic pain maintenance through neuroinflammatory mechanisms that were largely unrecognized before the 2000s. Ji et al. 2013 (Nature Reviews Neuroscience) established microglia as essential contributors to central sensitization: after nerve injury or chronic nociceptive input, microglia activate, release pro-inflammatory cytokines (IL-1β, TNF-α, IL-6), and facilitate synaptic strengthening between primary afferent neurons and spinal dorsal horn neurons through BDNF/TrkB signaling — creating a self-perpetuating neuroinflammatory loop.
Systemic inflammation amplifies central neuroinflammation via multiple pathways: peripheral inflammatory cytokines cross the blood-brain barrier at circumventricular organs; vagal afferent nerves transmit inflammatory signals to the hypothalamus and brainstem; activated astrocytes respond to systemic lipopolysaccharide (LPS from gut dysbiosis) with pro-inflammatory phenotype changes. This provides a mechanistic basis for why systemic anti-inflammatory interventions — dietary modification, omega-3 fatty acids, gut microbiome restoration — improve chronic pain conditions beyond any direct analgesic effect on the peripheral pain source.
The Opioid Epidemic and Opioid-Induced Hyperalgesia
The United States consumed 80% of global opioid supply at the peak of the prescribing epidemic — a pharmacological experiment without precedent in medical history. The consequences are documented: 75,000+ opioid overdose deaths in 2021 (CDC), with prescription opioid deaths as the leading driver before heroin and fentanyl complications surpassed them. But the functional pain medicine concern extends beyond addiction: opioid-induced hyperalgesia (OIH) — paradoxical pain sensitization caused by opioid use itself — represents a neurobiological consequence that progressively worsens pain despite (or because of) opioid therapy.
Lee et al. 2011 (Pain Physician) documented OIH mechanisms: mu-opioid receptor desensitization, spinal dynorphin upregulation (which activates NMDA receptors and increases substance P), central noradrenergic sensitization, and glial activation producing pro-nociceptive cytokines. The practical result: patients on long-term opioids for chronic non-cancer pain frequently develop worsening pain intensity despite dose escalation — a phenomenon often misinterpreted as disease progression requiring more opioids, creating a negative spiral. Recognition of OIH is essential for rational chronic pain management.
Low Dose Naltrexone: The Glial Modulator
Low dose naltrexone (LDN, 1.5-4.5mg nightly) represents one of the most compelling — and underutilized — interventions in functional pain medicine. At doses approximately one-tenth the standard addiction reversal dose (50mg), naltrexone’s antagonism of the TLR4 (Toll-like receptor 4) on microglia and astrocytes produces paradoxical anti-neuroinflammatory effects through a completely different mechanism than its mu-opioid receptor effects.
Younger and Mackey 2009 (Pain Medicine) double-blind RCT demonstrated that LDN 4.5mg reduced fibromyalgia pain by 30% versus placebo, with 57% of participants experiencing a meaningful response — remarkable for a repurposed generic medication. Younger et al. 2013 RCT confirmed these findings with improved symptom severity and mechanical temporal summation. Cree et al. 2010 RCT (n=80) showed LDN significantly improved quality of life in multiple sclerosis patients. Segal 2011 open-label Crohn’s disease study demonstrated 88% patient response rate with clinical remission in 33%. The glial TLR4 mechanism makes LDN a rational intervention across multiple central sensitization conditions — fibromyalgia, ME-CFS, MS, IBD, and CRPS — and the evidence base continues growing.
Dietary Anti-Inflammatory Interventions for Chronic Pain
The relationship between diet and chronic pain operates through multiple pathways: systemic inflammatory mediators, gut microbiome production of pain-modulating metabolites, glycemic variability (driving cortisol and inflammatory responses), and direct neuroinflammatory dietary triggers. A precision dietary approach to chronic pain addresses each mechanism:
Omega-3 fatty acids: Maroon and Bost 2006 (Surgical Neurology) RCT demonstrated that fish oil (1,200mg omega-3 daily) reduced neck and back pain equivalently to NSAIDs in spinal pain patients — with 59% discontinuing NSAIDs entirely. Goldberg and Katz 2007 meta-analysis confirmed omega-3’s anti-inflammatory effects translating to clinical pain reduction. The EPA:DHA ratio matters: EPA predominantly inhibits prostaglandin E2 synthesis; DHA reduces neuroinflammatory prostaglandins and leukotrienes at the brain level. Combined supplementation at 2-3g EPA+DHA daily achieves the tissue omega-3 index (above 8%) associated with pain reduction.
Elimination diets for food sensitivity-driven pain: Multiple mechanisms link food sensitivities to systemic pain: IgG-mediated immune complex formation triggering complement-driven inflammation; intestinal permeability (“leaky gut”) allowing bacterial LPS entry driving systemic inflammation (Fasano 2012); FODMAP intolerance producing visceral hypersensitivity and referred pain; and nightshade alkaloids (solanine, tomatine) potentially promoting neuroinflammation in susceptible individuals. An IgG food sensitivity panel (Cyrex Array 10 or Genova IgG) combined with systematic elimination of top reactors and reintroduction protocol identifies dietary pain drivers in 6-8 weeks.
Evidence-Based Supplements for Chronic Pain
Several supplements have meaningful RCT evidence for chronic musculoskeletal and neuropathic pain:
Curcumin (bioavailable formulations): Kuptniratsaikul et al. 2014 RCT (n=367) demonstrated curcumin equivalent to ibuprofen for knee osteoarthritis pain. Chandran 2012 RCT showed 18.7% ACR response in RA patients with curcumin — superior to diclofenac. Mechanism: NF-κB inhibition, COX-2 suppression, and inflammatory cytokine downregulation. Bioavailability is critical: standard curcumin powder is poorly absorbed; phospholipid complex (Meriva), piperine-enhanced (95% curcuminoids + BioPerine), or nanoparticle forms achieve 29-185× higher plasma concentrations. Dose: 1-4g bioavailable curcumin daily.
Palmitoylethanolamide (PEA): Endogenous lipid mediator modulating mast cell and glial activation via PPARα and CB2 receptors — the endocannabinoid system adjacent pathway. Meta-analysis by Hesselink 2013 of 12 controlled trials found highly significant pain reduction across multiple conditions including chronic pain, carpal tunnel, dental pain, and pelvic pain. PEA has emerged as a particularly compelling functional medicine option for neuropathic pain and central sensitization conditions, with good tolerability profile.
Magnesium: NMDA receptor antagonism makes magnesium a rational intervention for central sensitization. Magnesium blocks the NMDA receptor channel in a voltage-dependent manner — preventing the calcium influx that drives central sensitization amplification. Yousef and Al-deeb 2013 RCT demonstrated IV magnesium significantly reduced neuropathic pain scores. Oral magnesium glycinate (400-800mg) is appropriate for the majority of patients given the prevalence of magnesium deficiency.
Frequently Asked Questions
What is central sensitization and how is it treated?
Central sensitization is the amplification of pain signals within the spinal cord and brain — making the nervous system hypersensitive so normal stimuli produce pain, and painful stimuli produce disproportionate pain. It underlies fibromyalgia, chronic fatigue, IBS, and many chronic pain conditions. Treatment targets the amplification mechanism: low-dose naltrexone (LDN) for glial modulation, anti-inflammatory diet, omega-3 fatty acids, magnesium (NMDA antagonism), pain neuroscience education, graded exercise, and cognitive behavioral therapy for pain (CBT-P).
Can opioids make chronic pain worse?
Yes — through opioid-induced hyperalgesia (OIH). Long-term opioid use activates spinal dynorphin, NMDA receptors, and microglial neuroinflammatory pathways, paradoxically increasing pain sensitivity. Patients on long-term opioids may experience worsening pain despite dose escalation — a pharmacological consequence often misinterpreted as disease progression. Supervised opioid tapering combined with multi-modal pain management strategies (LDN, exercise, anti-inflammatory diet, CBT-P) can improve pain outcomes while reducing opioid burden.
Is there evidence that diet affects chronic pain?
Yes — through multiple mechanisms. Fish oil (1,200mg omega-3 daily) reduced spinal pain equivalent to NSAIDs in a published RCT, with 59% of patients discontinuing NSAIDs. Curcumin was equivalent to ibuprofen for knee osteoarthritis in an n=367 RCT. Mediterranean dietary pattern consistently reduces systemic inflammatory markers that drive central sensitization. Gut dysbiosis → LPS → neuroinflammation → central sensitization provides the mechanistic link between gut health and chronic widespread pain.
What is low dose naltrexone (LDN) and is it safe?
LDN uses naltrexone at 1.5-4.5mg — approximately 10% of the standard 50mg addiction reversal dose. At this low dose, it modulates microglial and astrocyte TLR4 receptors, reducing neuroinflammation rather than blocking opioid receptors. It is generally well-tolerated; the most common side effects are vivid dreams and mild sleep disruption in the first 1-2 weeks. LDN requires prescription (compounded through specialty pharmacies). It should not be used in patients actively taking opioids. RCT evidence supports benefit in fibromyalgia, MS, Crohn’s disease, and other central sensitization conditions.
Chronic pain is not a life sentence — it is a neurobiological condition with identifiable drivers and targeted treatment options beyond analgesics and opioids. At The Private Practice, we use functional pain medicine evaluation to identify central sensitization, neuroinflammatory drivers, and dietary contributors to your pain — creating a comprehensive, evidence-based treatment plan. Call (810) 206-1402 to schedule your chronic pain evaluation.